Syphilis Testing Market (2025 - 2033) Size Share & Trends Analysis Report By Technology (Molecular Diagnostics, Immunoassay), By Location of Testing (Laboratory Testing, Point Of Care Testing), By Region, And Segment Forecasts

Syphilis Testing Market Summary

The global syphilis testing market size was estimated at USD 515.21 million in 2024 and is projected to reach USD 1,375.60 million by 2033, growing at a CAGR of 11.89% from 2025 to 2033. Key market growth drivers for dual HIV/syphilis rapid diagnostics include the rising global burden of congenital syphilis and HIV co-infections, which continue to cause significant adverse pregnancy outcomes.

Growing emphasis on elimination of mother-to-child transmission (EMTCT) programs by the WHO and national health bodies is creating strong demand for cost-effective, point-of-care solutions. Regulatory approvals, such as Health Canada’s clearance of MedMira’s Multiplo Rapid TP/HIV Test, and partnerships like CHAI-MedAccess-SD Biosensor, are accelerating adoption by ensuring affordability and accessibility. Additionally, the push for decentralized testing in rural and underserved regions supports uptake, while technological improvements in accuracy and speed enhance market confidence.

Syphilis, once considered a disease of the past, has reemerged as a significant public health and market concern in North America and globally. While the widespread use of penicillin in the mid-20th century had nearly eliminated syphilis in high-income countries, recent years have seen a sharp resurgence. In the U.S., reported cases increased by more than 80% between 2018 and 2022, rising from approximately 115,000 to over 207,000-the highest level since the 1950s. Of particular concern is congenital syphilis, which grew by 183% during the same period, reflecting gaps in maternal screening and early intervention. In Canada, rising incidence in the Prairie provinces and northern territories-particularly among Indigenous populations further highlights disparities in access to timely diagnostics and treatment. These epidemiological shifts are creating heightened demand for innovative diagnostic solutions, decentralized testing models, and scalable public health interventions, positioning the infectious disease diagnostics market for accelerated growth.

Regulatory Shifts and Diagnostic Innovation in the U.S.

One of the most significant regulatory milestones came in August 2024, when the U.S. Food and Drug Administration (FDA) authorized the First To Know Syphilis Test from NOWDiagnostics, Inc.-the first over-the-counter, at-home syphilis antibody test available in the U.S. The device uses a finger-stick blood sample and provides results in about 15 minutes, delivering a level of accessibility comparable to at-home pregnancy or COVID-19 tests. Although the test cannot distinguish between past and current infection, since it only detects antibodies, the FDA’s decision to approve it through the De Novo pathway was groundbreaking. This regulatory classification not only recognizes the urgent public health need but also lowers barriers for future developers, effectively opening the market to additional consumer-friendly syphilis diagnostics.

The FDA’s action aligns with broader federal strategies. In 2024, the Department of Health and Human Services (HHS) launched the National Syphilis and Congenital Syphilis Syndemic Federal Task Force to coordinate response strategies across federal agencies. Together, these measures represent a new era of urgency, where regulatory flexibility and innovation are central to tackling an epidemic once thought to be under control.

NIH Investment in Next-Generation Testing

Complementing regulatory progress, the U.S. National Institutes of Health (NIH) has scaled up investment in syphilis research. In 2024, NIH awarded $2.4 million in grants to institutions, including the University of Washington and Johns Hopkins University, to develop diagnostics that move beyond antibody detection. Projects include mass spectrometry platforms capable of identifying syphilis proteins directly, aptamer-based DNA assays for rapid point-of-care use, and infant-specific diagnostics to address the congenital crisis. In 2025, NIH further expanded this portfolio, awarding $2.7 million to Penn State to support the development of an electrochemical biosensor that can detect both treponemal and non-treponemal antibodies in a single step within 10 minutes. This innovation could collapse the cumbersome two-test algorithm into a one-step process, transforming clinical workflows and enabling real-time, confirmatory diagnosis in both resource-rich and resource-limited settings.

Clinical and Community Strategies

Parallel to research and regulatory activity, implementation models are evolving. A 2024 study at the University of Chicago demonstrated that routine opt-in syphilis screening in emergency departments more than doubled case detection, particularly among asymptomatic patients and pregnant individuals. Such findings underscore how expanding testing criteria in high-throughput clinical environments can serve as critical intervention points.

Meanwhile, community-driven responses are making headway. In the Navajo Nation, mobile outreach teams have pioneered on-site testing and same-day treatment at food pantries, jails, and motels. This approach addresses a key weakness of traditional care pathways, loss to follow-up, and has shown that culturally grounded, flexible models can effectively reach vulnerable populations.

Canadian Advances: MedMira and Indigenous-Led Programs

In Canada, public health officials face many of the same diagnostic and treatment challenges as their U.S. counterparts, but with distinct regional dynamics. Between 2018 and 2024, syphilis incidence surged in the Prairie provinces, particularly Manitoba, Saskatchewan, and Alberta-where Indigenous populations are disproportionately affected. In March 2025, the Canadian Institutes of Health Research (CIHR), in partnership with Indigenous leaders, launched the Ayaangwaamiziwin Centre, an Indigenous-led initiative backed by over $7 million in funding to deliver testing, treatment, and culturally safe care in Prairie and northern communities. This program reflects a recognition that Indigenous leadership and community control are central to effective outbreak response.

On the regulatory side, Health Canada approved MedMira’s Multiplo TP/HIV Rapid Test on 26 December 2024, marking another turning point. The finger-prick device simultaneously detects HIV-1/2 and syphilis antibodies with results in minutes and requires no specialized storage, making it well-suited for clinics, hospitals, and remote communities. A 2020-2022 clinical study in Alberta, co-led by Dr. Sean Rourke (REACH Nexus, St. Michael’s Hospital, Toronto) and Dr. Ameeta Singh (University of Alberta), involving more than 1,500 participants, demonstrated 100% accuracy for HIV and over 98% accuracy for syphilis. Already deployed in Europe and Colombia, the test is being rolled out in Canada in collaboration with REACH Nexus. MedMira’s CEO, Hermes Chan, highlighted its ability to bridge diagnostic gaps at a fraction of conventional costs. Following this license, Health Canada is expected to authorize the Reveal TP (Syphilis) test in 2025, further strengthening the country’s diagnostic capacity.

Global Context: Dual-Testing and Maternal Health

These North American advances are part of a broader global transformation in syphilis diagnostics. On 15 November 2021, MedAccess, the Clinton Health Access Initiative (CHAI), and SD Biosensor launched a partnership to provide the STANDARD Q HIV/Syphilis Combo test at under US$1 across more than 100 low- and middle-income countries. This WHO-prequalified rapid test delivers results in under 20 minutes and is particularly aimed at antenatal care programs. Supported by a volume guarantee, the agreement reduced test prices by 32%, making it the lowest-cost WHO-endorsed dual test available at scale.

The global burden of congenital syphilis remains devastating. The infection causes an estimated 355,000 adverse pregnancy outcomes each year, including 210,000 stillbirths and neonatal deaths. In Africa, syphilis accounts for approximately 11% of all stillbirths. The World Health Organization projects that scaling dual HIV/syphilis testing in the 20 highest-burden countries could save 74,000 lives and prevent 53,000 severe illness cases annually. These efforts also align with global strategies to eliminate mother-to-child transmission (EMTCT) of HIV, syphilis, and hepatitis B.

Challenges and the Road Ahead

Despite these advances, critical challenges remain. Diagnostic technologies are still dominated by antibody-based assays, which cannot definitively confirm active infection or determine cure. Treatment depends almost exclusively on Bicillin L-A (benzathine penicillin G), a formulation with limited suppliers and frequent global shortages. No vaccine exists, leaving prevention dependent on timely detection, partner notification, and consistent drug supply. Moreover, public health funding has not kept pace with the epidemic. In the U.S., CDC funding for STD prevention dropped from $169 million in 2003 to about $80 million by 2023, even as cases more than doubled. Canadian public health programs face similar budgetary and access constraints, particularly in rural and northern regions.

Yet the convergence of regulatory approvals, NIH-funded research, Indigenous-led programs, and global partnerships offers cautious optimism. The FDA’s De Novo pathway for at-home testing sets a precedent for consumer-friendly innovations. NIH investments are driving technologies that could provide real-time, confirmatory results and infant-specific Location of Testings. Health Canada’s MedMira approval and CIHR’s Indigenous partnerships show how national strategies can integrate technology with community-led care. Globally, partnerships like CHAI and SD Biosensor demonstrate that equitable access and affordability are achievable at scale.

Market Concentration & Characteristics

Innovation in the syphilis testing market is reshaping dual rapid testing, with companies like MedMira launching the Multiplo Rapid TP/HIV Test, capable of detecting both HIV-1/2 and syphilis antibodies from a single finger-prick with 100% HIV accuracy and 98% syphilis accuracy. Already deployed in Europe and Colombia and recently approved by Health Canada (Dec 2024), such devices offer immediate results without refrigeration. This innovation supports decentralized care, bridging gaps in underserved communities and advancing EMTCT goals.

M&A and collaborations are driving accessibility and affordability. For instance, in November 2021, MedAccess, CHAI, and SD Biosensor formed a partnership to distribute the STANDARD Q HIV/Syphilis Combo Test at under US$1 across 100+ LMICs. While outright acquisitions are moderate, such global collaborations mirror consolidation effects, enabling scale, affordability, and distribution synergies. Larger diagnostics firms are expected to target similar partnerships or acquisitions to strengthen infectious disease testing portfolios.

Regulation remains a catalyst, shaping adoption and market entry. Health Canada’s approval (Dec 2024) of MedMira’s dual test followed a 1,500+ subject clinical study in Alberta (2020-2022) co-led by top institutions, ensuring credibility. Similarly, the WHO prequalification of SD Biosensor’s STANDARD Q combo test allowed procurement by donor-funded programs in LMICs. Such regulatory endorsements reduce market hesitancy, ensure compliance with global EMTCT strategies, and create strong differentiation for approved products.

In the syphilis testing, the substitution risk exists but remains manageable. Traditional ELISA and PCR assays deliver gold-standard accuracy but are limited by infrastructure needs and slower turnaround. Rapid combo tests, like MedMira’s Multiplo and SD Biosensor’s STANDARD Q, provide point-of-care results in under 20 minutes at a fraction of the cost. However, emerging HIV self-tests and multiplex molecular platforms could act as substitutes. To maintain an edge, rapid test developers emphasize affordability (e.g., 32% price cut via CHAI-MedAccess) and ease of use.

End users are highly concentrated in public health agencies, NGOs, and maternal health programs. For example, the CHAI-MedAccess-SD Biosensor partnership directly targets antenatal care in 100+ LMICs, aligning with WHO EMTCT goals. In high-income regions, adoption depends on government approvals, as seen with Health Canada’s 2024 clearance enabling rollout in Canadian hospitals and clinics. Indigenous populations in Canada’s Prairie provinces, experiencing disproportionately higher infection rates, highlight the need for targeted community health programs.

Technology Insights

The immunoassay segment led the syphilis testing market with the largest revenue share of 43.95% in 2024. Its dominance stems from widespread clinical adoption, established use in hospital laboratories, cost-effectiveness, and compatibility with high-throughput platforms. Immunoassays, including ELISA and chemiluminescent assays, are considered the gold standard for antibody detection, particularly in confirmatory testing. Their strong regulatory acceptance and extensive integration into public health programs further consolidate market leadership.

By contrast, molecular diagnostics represents the fastest-growing technology segment, driven by rising demand for early, highly sensitive detection of infections. PCR and next-generation sequencing (NGS)-based tools are gaining traction, particularly in monitoring viral load, resistance mutations, and detecting low-titer infections that may be missed by serology. Growth is accelerated by decentralization trends, falling costs of molecular platforms, and integration into point-of-care and multiplex assays. These attributes make molecular diagnostics critical in addressing gaps left by traditional methods, particularly in mother-to-child transmission screening and high-burden geographies.

Location of Testing Insights

The laboratory-based testing segment led the syphilis testing industry with the largest revenue share of 59.52% in 2024. The segment continues to represent the largest share owing to its entrenched role as the clinical gold standard. Centralized laboratories and hospital-based diagnostic centers rely heavily on automated immunoassays, ELISAs, and confirmatory treponemal/non-treponemal workflows that ensure high accuracy and consistency. These platforms support large-scale testing volumes, making them particularly valuable in national screening initiatives and prenatal care programs where reliability is paramount.

In the United States, laboratory giants such as Quest Diagnostics and LabCorp have built extensive syphilis testing infrastructure, often bundled with comprehensive STD panels that streamline testing workflows for clinicians. In Canada, providers such as LifeLabs and provincial public health labs dominate, integrating syphilis testing into routine sexual health and antenatal programs. Laboratories also benefit from established reimbursement pathways and integration with electronic medical records (EMRs), reinforcing their central role in healthcare systems.

Despite the growth of decentralized alternatives, laboratories continue to maintain their dominance because of their unmatched ability to handle confirmatory testing, complex case management, and integration with advanced molecular diagnostics. Particularly for high-risk populations and congenital syphilis investigations, laboratory workflows remain essential for providing definitive results.

Point-of-care (POC) testing is experiencing the fastest growth, reflecting shifting public health priorities toward accessibility, speed, and patient-centered care. The surge in congenital syphilis, which demands immediate detection and treatment, has highlighted the limitations of lab-centric models that rely on multiple visits and long turnaround times. In response, both regulators and companies are accelerating the adoption of rapid and at-home testing solutions. A landmark example is Health Canada’s approval (December 2024) of MedMira’s Multiplo Rapid TP/HIV Test, a dual-purpose finger-prick device that delivers near-instant results for both HIV and syphilis without special storage requirements. Already in use across Europe and Colombia, the device is now positioned to close diagnostic gaps in both urban hospitals and remote Canadian communities. Similarly, in August 2024, the U.S. FDA authorized NOWDiagnostics’ First To Know Syphilis Test through the De Novo pathway, marking the first over-the-counter syphilis diagnostic available for at-home use. This regulatory milestone not only enables consumer-driven testing but also establishes a precedent for other developers to bring innovative syphilis POC solutions to market.

POC solutions are particularly critical in Indigenous and underserved communities across North America, where access to centralized laboratories is limited and travel times are prohibitive. Mobile outreach programs in regions like the Navajo Nation in the U.S. and Prairie provinces in Canada are leveraging these rapid devices to deliver same-day testing and treatment, reducing loss to follow-up. Globally, WHO-endorsed dual HIV/syphilis combo tests, such as the STANDARD Q (SD Biosensor) supplied under the CHAI-MedAccess partnership, are further demonstrating the role of POC platforms in advancing elimination of mother-to-child transmission (EMTCT) targets. As syphilis rates rise, the market is shifting toward hybrid models, where centralized labs maintain their dominance for confirmatory and large-scale screening. At the same time, POC testing grows rapidly as a frontline solution to improve accessibility, equity, and speed of diagnosis.

Regional Insights

North America held the dominant position in the syphilis testing market in 2024, capturing 40.17% of the revenue share. The U.S. drives this leadership through high testing volumes at Quest Diagnostics, Labcorp, and public health laboratories, where syphilis is included in comprehensive STD panels. Recent FDA clearances of innovative diagnostics, such as NOWDiagnostics’ at-home syphilis test, are expanding access and creating a consumer-directed market. In Canada, LifeLabs and provincial health authorities emphasize antenatal screening and community outreach programs, particularly in the Prairie provinces. Growing congenital syphilis rates and strong federal funding continue to fuel demand across both laboratory and point-of-care channels.

U.S. Syphilis Testing Market Trends

The U.S. syphilis testing industry’s growth is driven by a sharp epidemiologic rebound-reported cases rose ~80% from 2018 to 2022-plus major policy and regulatory responses. The FDA’s August 2024 De Novo authorization for NOWDiagnostics’ at-home antibody test created an OTC consumer testing channel. NIH investments ($2.4M in 2024; $2.7M in 2025 grants) are accelerating next-gen molecular and electrochemical POC diagnostics. Implementation models (e.g., University of Chicago ED opt-in screening; Navajo Nation mobile outreach) emphasize decentralized testing and same-day treatment to reduce loss to follow-up. Persistent challenges-Bicillin L-A shortages, declining CDC STD prevention funding, and congenital syphilis spikes-sustain demand for rapid, confirmatory, and field-deployable tests.

Europe Syphilis Testing Market Trends

Europe’s syphilis testing industry is shaped by growing incidence and strong national health systems prioritizing targeted screening. The UK and Germany report steady case increases, prompting expansion of free sexual health services and antenatal programs. Laboratories dominate with automated immunoassays, while CE-marked rapid tests are used in community clinics. Digital integration into public health networks improves surveillance and contact tracing. Procurement remains cost-sensitive, requiring value-driven pitches from suppliers. Future growth is likely through dual HIV/syphilis rapid tests in antenatal care, and enhanced use of digital reporting platforms. Strong regulation and robust reimbursement systems create barriers but ensure market stability.

The syphilis testing market in the UK showcases modest upticks in syphilis diagnoses (early-stage cases: 9,535 in 2024 vs 9,375 in 2023; overall cases 13,030 vs 12,456). Public programs emphasize free, confidential testing and targeted messaging to high-risk groups (MSM, young adults). Policy momentum-NHS rollout of gonorrhoea vaccination programs-illustrates prevention orientation, while surveillance highlights rising antibiotic resistance in gonorrhoea. Market opportunities center on integrated sexual-health POC devices and digital linkage-to-care solutions. Buyers favor validated rapid dual tests for antenatal screening and community clinics; regulatory acceptance and NHS procurement cycles will determine commercial scale-up.

Germany’s syphilis testing market landscape mirrors broader EU increases in bacterial STIs; testing and genomic surveillance (WGS) are expanding to track resistant strains. Clinical laboratories remain primary purchasers, using automated immunoassays for screening and molecular techniques for complex cases. Growing public-health focus on MSM and young adult engagement, plus improved surveillance, is creating demand for rapid POC diagnostics in sexual-health clinics and outreach programs. Vendors that combine high sensitivity with integration into municipal public-health reporting and partner-notification workflows will find traction as Germany scales targeted screening and antimicrobial-resistance monitoring.

Asia Pacific Syphilis Testing Market Trends

The Asia Pacific syphilis testing industry is projected to showcase significant growth at a CAGR of 15.8% over the forecast period. Asia Pacific presents diverse dynamics, with China and Japan leading in laboratory-based immunoassays and antenatal screening, while Southeast Asia emphasizes cost-effective rapid testing. Rising incidence, urbanization, and maternal health programs drive demand. China’s provincial procurement favors high-volume labs and WHO-prequalified dual tests, while Japan expands targeted syphilis clinics but requires rigorous validation for new technologies. In lower-income countries, donor-driven programs supply affordable rapid kits for maternal health. Market opportunities lie in combining rapid testing with digital follow-up, ensuring timely treatment. Strategic partnerships and localized regulatory alignment are critical for success in this fragmented yet high-growth regional market.

China’s syphilis testing market is characterized by expanding laboratory capacity and rapid scale-up of point-of-care screening in urban and provincial health systems. National antenatal screening initiatives and rising STI surveillance drive demand for affordable dual HIV/syphilis rapid assays, lab immunoassays, and molecular confirmatory tests. Manufacturers that offer WHO-aligned, low-cost combo tests and scalable platforms can access procurement through provincial health networks. Challenges include bridging urban-rural access gaps and ensuring confirmatory lab follow-through; opportunities exist for POC integration with telemedicine and maternal health programs.

The syphilis testing market in Japan is expected to grow over the forecast period. Japan has responded to localized outbreaks-Tokyo reported 3,667 syphilis cases in 2022 (a 50% rise from 2021)-by expanding testing access (extended clinic hours, holiday/Sunday services) and pairing syphilis with HIV screening. The market is conservative, favoring laboratory immunoassays for confirmatory diagnosis, but authorities are piloting POC expansions to improve early detection in young adults. Vendors should prioritize regulatory compliance, clinician education, and demonstration projects tied to prenatal care; culturally sensitive outreach and anonymity-preserving distribution channels will support uptake among younger and stigmatized populations.

Latin America Syphilis Testing Market Trends

Latin America, led by Brazil, prioritizes syphilis testing within maternal and child health programs due to high congenital syphilis rates. Public procurement dominates, with Ministries of Health sourcing WHO-prequalified dual HIV/syphilis tests for antenatal care. Laboratories remain important for confirmatory testing, but POC diagnostics in community clinics are increasingly adopted to enable same-visit treatment initiation. Brazil’s federal health system purchases at scale, driving strong demand for affordable, reliable supply chains. The region’s price sensitivity favors cost-effective solutions, and partnerships with local distributors and NGOs are essential. Demonstrating improved maternal outcomes is key to sustained growth and procurement renewals.

The Brazil syphilis testing market is expected to grow over the forecast period. Brazil’s public health priorities emphasize antenatal screening and reducing congenital syphilis, creating sizable demand for dual HIV/syphilis rapid tests and low-cost POC kits. Regional initiatives and NGO partnerships (mirrored by CHAI/MedAccess/SD Biosensor models) have created price-sensitive procurement channels across LMICs. Large public purchasers (Ministry of Health, regional health secretariats) prioritize WHO-prequalified products that enable on-site testing in primary care and maternity clinics. Vendors that can combine cost competitiveness, supply reliability, and integration with prenatal programs will be well-positioned to scale across Brazil and neighboring markets.

Middle East and Africa Syphilis Testing Market Trends

In Africa, syphilis remains a major driver of adverse birth outcomes-~11% of stillbirths are attributable to syphilis-so maternal screening is a key market. WHO and donor-funded procurement drive uptake of low-cost, WHO-prequalified combo tests (e.g., STANDARD Q). Infrastructure constraints favor POC and rapid combo diagnostics that do not require a cold chain or complex lab infrastructure. In the Middle East, markets are heterogeneous: wealthier GCC countries invest in lab and molecular capacity, while low-resource countries rely on NGO and donor programs. Scalability depends on procurement frameworks, donor support, and local capacity-building.

The Saudi Arabia syphilis testing market is projected to grow during the forecast period. Saudi Arabia’s health system emphasizes centralized lab capacity and antenatal screening within public hospitals; demand for high-quality immunoassays and molecular confirmatory testing remains strong. At the same time, Gulf Cooperation Council (GCC) initiatives and private hospitals are open to rapid POC solutions for screening travelers, migrant worker clinics, and perinatal care. Market entry requires regulatory clearance, adherence to national procurement, and partnerships with major hospital groups. Opportunities exist for accredited dual HIV/syphilis rapid tests that meet Saudi regulatory standards and can be deployed in maternal health and occupational-health screening programs.

Key Syphilis Testing Company Insights

Market leaders are involved in extensive R&D for manufacturing technologically advanced, cost-efficient testing products. Besides, several strategies, such as mergers & acquisitions, are being incorporated by various organizations to expand their market presence and are anticipated to create significant growth opportunities over the forecast period. For instance, in May 2023, Charles Thermo Fisher Scientific, Inc. entered into a partnership with Pfizer Inc. to enhance the availability of localized access to next-generation sequencing-based testing for cancer patients in international markets.

Recent Developments

1. First To Know Syphilis Test by NOWDiagnostics, Inc.

Date: August 2024

The U.S. FDA authorized the First To Know Syphilis Test by NOWDiagnostics, Inc., the first over-the-counter, at-home syphilis antibody test. Using a finger-stick blood sample, it delivers results in 15 minutes, similar to pregnancy or COVID-19 home tests. Although it cannot differentiate between past and active infections, its approval via the De Novo pathway reflects regulatory recognition of urgent public health needs. This milestone lowers barriers for consumer-focused diagnostics and sets a precedent for rapid, accessible syphilis testing. Enabling at-home testing expands early detection, reduces transmission, and empowers individuals to seek timely care.

2. NIH-Funded Next-Generation Diagnostics Research

Date: 2024-2025

The U.S. National Institutes of Health (NIH) invested heavily in innovative syphilis diagnostics, awarding $2.4 million in 2024 and $2.7 million in 2025. Projects include mass spectrometry platforms for direct detection of syphilis proteins, aptamer-based DNA assays for rapid point-of-care use, and infant-specific diagnostics addressing congenital syphilis. Penn State researchers developed an electrochemical biosensor capable of detecting treponemal and non-treponemal antibodies in 10 minutes, potentially collapsing the traditional two-step testing algorithm into a single step. These investments aim to improve real-time, confirmatory diagnosis, enhance clinical workflows, and address gaps in both resource-rich and resource-limited healthcare settings globally.

3. National Syphilis and Congenital Syphilis Syndemic Task Force

Date: 2024

The U.S. Department of Health and Human Services (HHS) launched the National Syphilis and Congenital Syphilis Syndemic Federal Task Force to coordinate cross-agency strategies for outbreak response. This initiative aligns regulatory flexibility, diagnostic innovation, and public health programming to address surging syphilis rates, including a concerning rise in congenital infections. The task force facilitates policy alignment, data sharing, and resource allocation across federal, state, and local levels. By integrating testing, treatment, and prevention strategies, it strengthens national readiness, targets high-risk populations, and underlines the federal commitment to reversing decades of neglect in syphilis control and maternal-infant health outcomes.

4. Indigenous-Led Health Program - Ayaangwaamiziwin Centre

Date: March 2025

In Canada, the Canadian Institutes of Health Research (CIHR), in partnership with Indigenous leaders, established the Ayaangwaamiziwin Centre, a $7 million Indigenous-led initiative to combat syphilis in Prairie and northern communities. The program delivers culturally safe testing, treatment, and community-based care, addressing disproportionately high infection rates among Indigenous populations. By embedding community leadership and culturally appropriate approaches, it reduces barriers to access, improves follow-up adherence, and enhances trust in healthcare interventions. The initiative integrates modern diagnostics with mobile outreach strategies and local engagement, serving as a model for equitable public health interventions targeting vulnerable populations in both rural and urban settings.

5. Global Dual HIV/Syphilis Testing Partnership

Date: November 2021

MedAccess, the Clinton Health Access Initiative (CHAI), and SD Biosensor launched a global partnership to provide the STANDARD Q HIV/Syphilis Combo test at under US$1 across 100+ low- and middle-income countries. The rapid test, delivering results in under 20 minutes, is aimed primarily at antenatal care programs to prevent congenital syphilis and reduce mother-to-child transmission. Supported by a volume guarantee, the initiative reduced test prices by 32%, making it the lowest-cost WHO-prequalified dual test globally. By combining affordability, scalability, and rapid results, this partnership exemplifies a strategic approach to equitable diagnostics, maternal health, and global syphilis control efforts.

Syphilis Testing Market Report Scope

Global Syphilis Testing Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global syphilis testing market report based on technology, location of testing, cancer type, function, and region:

• Technology Outlook (Revenue, USD Million, 2021 - 2033)

  • Molecular Diagnostics

  • Immunoassay

  • Others

• Location of Testing Outlook (Revenue, USD Million, 2021 - 2033)

  • Laboratory Testing

    • Commercial/Private labs

    • Public Health Labs

  • Point of Care Testing

• Regional Outlook (Revenue, USD Million, 2021 - 2033)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Thailand

  • Latin America

    • Brazil

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait